Hyperbaric Oxygen Therapy (HBOT) in Chronic Traumatic Brain Injury (TBI)/Post Concussion Syndrome (PCS) and TBI/Post-Traumatic Stress Disorder (PTSD)

NCT ID: NCT00760734

Last Updated: 2017-04-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-09-30

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a pilot trial to see if one or two 40 treatment courses of low pressure hyperbaric oxygen therapy can improve cognition and brain imaging in subjects with either chronic mild-moderate traumatic brain injury (TBI), also known as post-concussion syndrome (PCS) or chronic PCS with post-traumatic stress disorder (PTSD) secondary to blast injury.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

TBI (Traumatic Brain Injury) Post Concussion Syndrome Post Traumatic Stress Disorder Chronic Post Traumatic Stress Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hyperbaric oxygen therapy-TBI/PCS

Intervention: Low pressure hyperbaric oxygen therapy, 40 or 80 twice daily, 5d/week, HBOTs at 1.5 ATA/60 minutes each. One month no treatment period between the 40th and 41st HBOT

Group Type EXPERIMENTAL

Low pressure hyperbaric oxygen therapy

Intervention Type DRUG

HBOT at 1.5 ATA/60 minutes twice/day, five days/week for 40 or 80 treatments

Low pressure hyperbaric oxygen therapy

Intervention Type DRUG

HBOT: 1.5 ATA/60 minutes twice/day, 5 days/week for 40 or 80 treatments

Hyperbaric Oxygen Therapy-PCS/PTSD

Intervention: Low pressure hyperbaric oxygen therapy, 40 or 80 twice daily, 5d/week, HBOTs at 1.5 ATA/60 minutes each. One month no treatment period between the 40th and 41st HBOT

Group Type EXPERIMENTAL

Low pressure hyperbaric oxygen therapy

Intervention Type DRUG

HBOT at 1.5 ATA/60 minutes twice/day, five days/week for 40 or 80 treatments

Low pressure hyperbaric oxygen therapy

Intervention Type DRUG

HBOT: 1.5 ATA/60 minutes twice/day, 5 days/week for 40 or 80 treatments

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Low pressure hyperbaric oxygen therapy

HBOT at 1.5 ATA/60 minutes twice/day, five days/week for 40 or 80 treatments

Intervention Type DRUG

Low pressure hyperbaric oxygen therapy

HBOT: 1.5 ATA/60 minutes twice/day, 5 days/week for 40 or 80 treatments

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

HBOT HBOT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults, 18-65 years old
* One or more mild-moderate TBI's characterized by loss of consciousness due to blast injury that is a minimum of one year old and occurred after 9/11/2001
* Absence of acute cardiac arrest or hemorrhagic shock at time of TBI.
* Absence of intracranial neurosurgery post-TBI
* Disability Rating Scale of 0-3
* Negative Michigan Alcohol Screening Test (MAST)
* Negative Drug Abuse Screening Test (DAST)
* Negative urine toxicology screen for drugs of abuse
* Negative pregnancy test in females
* Otherwise good health
* Less than 90% on the Percent Back to Normal Rating Scale

Exclusion Criteria

* Pulmonary disease that precludes HBOT
* Unstable medical conditions that are contraindicated in HBOT
* Severe confinement anxiety
* Pregnancy
* Other pre-TBI neurological diagnoses
* Pre or post TBI history of substance abuse
* Pre or post TBI history of alcoholism.
* Participation in another experimental trial with active intervention.
* High probability of inability to complete the experimental protocol.
* Previous HBOT
* History of hospitalization for past TBI, stroke, nonfebrile seizures, or any seizure history other than seizure at the time of TBI
* Past or current history of mental retardation (baseline FSIQ \< 71.
* Pre/post-TBI history of systemic illness with impact on CNS (P.I.'s decision)
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Semper Fi Fund

UNKNOWN

Sponsor Role collaborator

Marine Corps-Law Enforcement Foundation

OTHER

Sponsor Role collaborator

Coalition to Support America's Heroes

UNKNOWN

Sponsor Role collaborator

Thirty-eight other contributors

UNKNOWN

Sponsor Role collaborator

Paul G. Harch, M.D.

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Paul G. Harch, M.D.

Clinical Professor of Medicine

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Paul G Harch, M.D.

Role: PRINCIPAL_INVESTIGATOR

Louisiana State University Health Sciences Center in New Orleans

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

LSU Health Sciences Center

New Orleans, Louisiana, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Harch PG, Andrews SR, Fogarty EF, Amen D, Pezzullo JC, Lucarini J, Aubrey C, Taylor DV, Staab PK, Van Meter KW. A phase I study of low-pressure hyperbaric oxygen therapy for blast-induced post-concussion syndrome and post-traumatic stress disorder. J Neurotrauma. 2012 Jan 1;29(1):168-85. doi: 10.1089/neu.2011.1895. Epub 2011 Nov 22.

Reference Type RESULT
PMID: 22026588 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LSU IRB #7051

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Deep Brain Stimulation for Treatment Refractory PTSD
NCT03416894 ACTIVE_NOT_RECRUITING NA
Theta-Burst Neuromodulation for PTSD
NCT02769312 COMPLETED PHASE1/PHASE2
Non Invasive Brain Stimulation for PTSD
NCT02442843 COMPLETED EARLY_PHASE1
Deep Brain Stimulation for Refractory PTSD
NCT06705296 RECRUITING PHASE1
tDCS and Inhibitory Control in PTSD
NCT06100731 COMPLETED NA
Improving Cognitive Rehabilitation Outcomes
NCT07055633 NOT_YET_RECRUITING NA